Lilly drops out of IL-23 psoriasis race

[Fred]

Lilly have announced in their first quarter results that they will be dropping mirikizumab for psoriasis.

Quote:

---

The company announced that mirikizumab met the primary and all key secondary endpoints in a Phase 3 induction study evaluating the efficacy and safety of mirikizumab for the treatment of patients with moderate to severe ulcerative colitis.

The company announced that the development program for mirikizumab will henceforth focus on the ulcerative colitis and Crohn's disease indications.

While the OASIS program generated positive results for mirikizumab with safety and efficacy similar to other IL-23p19s, the company no longer plans to submit mirikizumab for regulatory approval in psoriasis in any geography.

Source: lilly.com

[KatT]

That's too bad but there's probably a good reason for it 

[Fred]

That's too bad but there's probably a good reason for it 

My understanding is that it was dropped from psoriasis because they thought there is too much competition in that market now with IL23

[KatT]

Not a good reason 

[Fred]

Not a good reason 

It is if you're a shareholder. You have to remember these companies are in it for the money, they have to keep their shareholders happy.